Last updated: April 2, 2026
What is the drug associated with NDC 72603-0600?
NDC 72603-0600 corresponds to Zolgensma (onasemnogene abeparvovec-xioi). It is a gene therapy developed by Novartis for spinal muscular atrophy (SMA) type 1, approved by the FDA in May 2019.
Market Size and Demand
Epidemiology and Patient Population
- SMA affects roughly 1 in 10,000 live births, with an estimated 400 to 1,200 new cases annually in the US.
- The therapy is indicated for pediatric patients under 2 years old, with early diagnosis critical for effectiveness.
- The US SMA market estimates approximate 300–500 eligible new patients annually.
Current Market Penetration
- Despite high costs, Zolgensma has captured a significant portion of the SMA treatment market.
- The market demonstrates high medicare and private insurer adoption, with coverage secured through negotiations.
- Estimated eligible patient treatment rate in the US is around 60–70% of newly diagnosed young children.
Competitive Landscape
- Other treatments include Spinraza (nusinersen) by Biogen and Evrysdi (risdiplam) by Roche.
- Spinraza, approved in 2016, has broader age indications.
- Price strategies differentiate therapies: Spinraza is given repeatedly, while Zolgensma is a one-time dose.
Market Dynamics
- The increasing adoption of newborn screening programs enhances early detection.
- Expansion into older SMA patients is limited; current focus is infants.
- Reimbursement policies heavily influence market penetration.
Price Analysis and Projections
Current Pricing
- List price for Zolgensma: approximately $2.1 million for a single-dose treatment (2019 USD).
- Pricing strategies position Zolgensma as a high-cost, one-time curative option relative to ongoing therapies.
Cost-Effectiveness and Payer Acceptance
- The high upfront price faces scrutiny but is viewed as cost-saving long-term due to reduced ongoing treatment costs.
- Several payers have negotiated outcomes-based agreements, limiting financial risk.
Future Price Trends
- No significant price reductions are anticipated in the near term due to the therapy's unique position as a potentially curative gene therapy.
- Some indications suggest a possible price adjustment to remain competitive with emerging therapies.
- Introduction of biosimilars or follow-on gene therapies could pressure prices over the next 5–10 years.
Projected Market Pricing
| Year |
Estimated Price (USD) |
Key Factors |
| 2023 |
$2.1 million |
Stabilized price; widespread adoption within eligible patients |
| 2025 |
$2.0 million |
Slight pressure from payor negotiations, market maturity |
| 2030 |
$1.8 million (forecast) |
Potential reductions due to market competition and new entrants |
Revenue Projections
- Global sales in 2022: approximately $1.04 billion (source: EvaluatePharma).
- US represents 60% of sales; rest comes from Europe and Asia.
- Sales are expected to grow, reaching an estimated $1.5–2 billion by 2025, contingent on market expansion and approvals in broader age ranges.
Regulatory and Policy Influences on Market Price
- Price negotiations are increasingly value-based, especially in the US, where CMS and private payers require evidence of long-term benefit.
- The FDA’s accelerated approval pathways and follow-on indications may influence pricing strategies.
- International markets may see lower prices due to price controls and pricing negotiations, particularly in Europe.
Key Takeaways
- NDC 72603-0600 (Zolgensma) commands a high price due to its curative potential.
- The marketed price remains stable around $2.1 million, with slight reductions projected over time.
- Market demand is driven by early diagnosis, newborn screening, and therapeutic efficacy.
- Competition from Spinraza and Evrysdi influences long-term pricing and market share.
- Revenue growth depends on expanding eligible patient populations and broader age approvals.
FAQs
1. What factors influence the price of Zolgensma?
The high development costs, one-time curative nature, and competitive positioning influence its price. Negotiations with payers and outcomes-based agreements also affect net pricing.
2. How does early diagnosis impact market demand?
Early diagnosis through newborn screening increases eligible patients, thereby driving demand and utilization of Zolgensma.
3. Are there plans to reduce Zolgensma’s price?
No announced plans for significant reductions; pricing remains high, supported by its perceived long-term value and curing potential.
4. How do payers assess the value of Zolgensma?
Payers evaluate based on long-term cost savings, clinical outcomes, and the rarity of SMA, often engaging in outcomes-based contracts.
5. What is the forecast for Zolgensma's global sales?
Sales are projected to grow to approximately $1.5–2 billion annually by 2025, driven by wider adoption, approvals, and market expansion.
References:
[1] EvaluatePharma. (2023). Gene Therapy Market Report 2023. Retrieved from https://www.evaluate.com
[2] U.S. Food and Drug Administration. (2019). FDA approvals: Zolgensma (onasemnogene abeparvovec-xioi). Retrieved from https://www.fda.gov
[3] Novartis. (2019). Zolgensma—Product information. Retrieved from https://www.novartis.com
[4] IQVIA. (2022). Global Oncology Market Data. Retrieved from https://www.iqvia.com
